Compare SLE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | CANF |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.5M |
| IPO Year | 2019 | N/A |
| Metric | SLE | CANF |
|---|---|---|
| Price | $0.51 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $9,750.00 |
| AVG Volume (30 Days) | 262.2K | ★ 564.4K |
| Earning Date | 11-13-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,568,000.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | $20.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $3.36 |
| 52 Week High | $26.00 | $46.60 |
| Indicator | SLE | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 73.84 |
| Support Level | $0.62 | $3.87 |
| Resistance Level | $0.76 | $4.43 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 9.11 | 83.09 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.